STRUCTURAL VALVE DETERIORATION
Valve durability remains the crux of discussion as the target population for TAVR evolves to include younger, low-risk patients (80% of patients with aortic stenosis undergoing surgery) who are likely to survive for a number of years after the procedure. The biological tissue from both surgical and transcatheter bioprostheses is prone to structural valve deteriora- between 10% and 20% in a 10-year period (4).
Nevertheless, when both morphological and hemodynamic valve deterioration using Doppler echocardiography are considered, the rates of bioprosthetic valve dysfunction are substantially higher (10% to 30% at 5 to 10 years post-SAVR) (9).
TAVR DURABILITY: WHEN THE DEFINITION OF SVD MATTERS!
In the field of TAVR, data on durability are currently with up to 50% SVD within 8 years after implantation, generating concern among the structural heart community regarding the durability of TAVR prostheses.
The investigators also noted gradually increasing calcification in the TAVR valve that progressed to valve degeneration within the first 5 years, with a Lancellotti et al. All-cause mortality at 6-year follow-up was similar in both groups (TAVR 42.5% vs. SAVR 37.7%), but rates of moderate to severe SVD were significantly higher after surgery (24.0% vs. 4.8%), whereas rates of non-SVD, endocarditis (5.9% vs. 5.8%), and BVF (6.7% vs. Lancellotti et al. 
